CTSH three-lens brief
Evidence-based stock research on CTSH. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 17.1pp over 30 days. · Trading at 3% of its 52-week range — deep in the lower band.
- Trading at 3% of its 52-week range — deep in the lower band.
- Underperforming SPY by 17.1pp over 30 days.
- Analyst mean target $82.60 — 50% above current (26 analysts).
- Debt-to-equity of 7.8 — balance-sheet-heavy.
CTSH closed at $55.11 (+0.02%) as of 2026-04-25. Market cap: $26.36B. P/E (trailing) 12.1. Positives: analyst mean target $82.60 — 50% above current (26 analysts).. Concerns: trading at 3% of its 52-week range — deep in the lower band.; underperforming SPY by 17.1pp over 30 days.. Last quarter: Revenue $5.33B, net income $648.00M, free cash flow $1.93B.
Why three lenses on CTSH, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CTSHacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CTSH" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CTSH brief"></iframe>